Ligand id: 9150

Name: naldemedine

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 7
Topological polar surface area 141.18
Molecular weight 570.25
XLogP 3.31
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Naldemedine is delivered clinically as the tosylate salt (PubChem CID 56837137). The drug has completed Phase 3 clinical trials to evaluate its efficacy in treating opioid-induced constipation (OIC) in patients receiving opioid analgesics for chronic pain. Click here to link to all naldemedine trials registered at Positive outcomes from a Phase 3 trial (called the COMPOSE I trial) as part of the COMPOSE program translated to US FDA approval (in 2017) as a once-daily treatment for opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.